Burling Wealth Partners LLC Makes New Investment in Zoetis Inc. (NYSE:ZTS)

Burling Wealth Partners LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 12,581 shares of the company's stock, valued at approximately $2,050,000.

Several other large investors also recently added to or reduced their stakes in ZTS. Callahan Advisors LLC increased its position in shares of Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after buying an additional 6,221 shares during the period. CIBC Asset Management Inc lifted its stake in Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after purchasing an additional 46,050 shares in the last quarter. Pensionfund Sabic grew its position in shares of Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock valued at $1,825,000 after purchasing an additional 4,000 shares in the last quarter. Schroder Investment Management Group increased its holdings in shares of Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after purchasing an additional 6,169 shares during the period. Finally, PFW Advisors LLC purchased a new stake in shares of Zoetis in the fourth quarter worth $1,764,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Trading Up 0.2 %

Shares of Zoetis stock traded up $0.31 on Monday, hitting $153.78. The stock had a trading volume of 1,873,396 shares, compared to its average volume of 2,498,843. The stock's 50-day simple moving average is $158.91 and its two-hundred day simple moving average is $168.32. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a market cap of $68.61 billion, a price-to-earnings ratio of 28.11, a PEG ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.30%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is currently 36.56%.

Insider Transactions at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Piper Sandler lifted their price target on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Stifel Nicolaus decreased their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Finally, StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $214.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.